Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
BMI Calculator
Collaborate
About
EQOH
Careers
Contact Us
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Work with Us
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
BMI Calculator
Collaborate
About
EQOH
Careers
Contact Us
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Work with Us
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Search type
Keyword
Author
Edition
European
US
Dermatology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Interviews
Podcasts
Videos & Webinars
News
Infographics
Society updates
Submit A Paper
Tildrakizumab After Anti-IL-17 Failure Improves Psoriasis Outcomes
November 2026
Tildrakizumab delivered sustained improvements in psoriasis severity, quality of life and treatment satisfaction after IL-17 inhibitor failure.
Read more
18 Nov 2026
Tildrakizumab After Anti-IL-17 Failure Improves Psoriasis Outcomes
Tildrakizumab delivered sustained improvements in psoriasis severity, quality of life and treatment satisfaction after IL-17 inhibitor failure.
16 Nov 2026
Alopecia Areata White Hair Growth Occurs Without Follicular Cycling
A large retrospective study found that alopecia areata-associated white hair affected 16% of patients, identifying three potential mechanisms and an association with ageing, autoimmunity and altered hair pigmentation.
13 Nov 2026
Evening Preference Linked to Inflammatory Skin Disease
An EPISONO study found evening preference was associated with higher odds of inflammatory skin disease and poorer psychological wellbeing.
11 Nov 2026
Psoriasis Linked to Wide Range of Long-Term Comorbidities
A UK longitudinal study found psoriasis was associated with numerous comorbidities across organ systems, including liver disease, substance misuse and respiratory disease.
9 Nov 2026
Psoriasis Linked to Higher Cataract Risk After Phototherapy
A study found psoriasis was associated with higher risks of cataract and cataract surgery, while PUVA and UVB phototherapy were linked to increased cataract odds.
6 Nov 2026
Parents of Children with Epidermolysis Bullosa Need Tailored Support
Parents of children with epidermolysis bullosa reported sadness, guilt and uncertainty, highlighting the need for tailored psychosocial interventions that address the wellbeing of the whole family.
4 Nov 2026
Estrogen Therapy and Increased Porphyria Cutanea Tarda Risk
A nationwide Danish study found that estrogen-containing therapy was associated with increased odds of porphyria cutanea tarda, with an association observed for oral but not non-oral administration.
2 Nov 2026
Mucous Membrane Pemphigoid Shows Site-Specific Remission Patterns
Multisite mucous membrane pemphigoid: only 45% achieved complete remission, with oral and ocular disease limiting treatment success.
Loading posts...
1
2
3
…
59
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View